The european stock exchanges play a maximum of one year after the offer of J&J by Actelion – Investing.com Spain

LONDON (Reuters) – european stocks escalated to a maximum of a year the Thursday after the news that Johnson & Johnson will buy the biotechnology switzerland Actelion (SIX:) in a transaction of 30,000 million dollars.

The giant american health products, will launch an offer in cash that provides for the segregation of the portfolio of R & D of Actelion. With the purchase, J&J access to drugs for rare diseases the group’s swiss, they have a high profit margin.

The actions of Actelion soared more than 20 per cent.

The general market also found support in reports of results such as those of the semiconductor manufacturer franco-Italian STMicroelectronics (PA:), which rose more than 6 percent after a couple of online accounts in the last quarter of 2016.

The index of the pan-european went up by 0.6 percent at 0819 GMT, local time, marking its best level since December 2015. The German marked its highest since may of 2016 and it advanced 0.7 percent.

legal Notice: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn’t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.